In conclusion, the identified VDAC1 binding site in SOD1, and the potential of this sequence as a cell-penetrating peptide to prevent mutant SOD1 cytotoxicity, provides an opportunity for the development of new ALS therapy. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.